Louvain-la-Neuve, Belgium, April 13, 2018, 17.35 - IBA (Ion Beam Applications SA), the world`s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue ...
Louvain-la-Neuve, Belgium, 20 November 2025 - IBA (Ion Beam Applications SA), the world leader in particle accelerator technology, shares its business update for the third quarter of 2025. Group ...
Louvain-La-Neuve, Belgium, March 22, 2018 - IBA (Ion Beam Applications SA, EURONEXT), the world`s leading provider of proton therapy solutions for the treatment of cancer, today announces its audited ...
Louvain-La-Neuve, Belgium, December 15, 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of proton therapy ...
In a report released on November 21, Matthias Maenhaut from Kepler Capital maintained a Sell rating on Ion Beam Applications SA IBA (0GZK – Research Report), with a price target of €11.75. The company ...
We have the honor of convening you to the Ordinary General Meeting (the "OGM") of IBA to be held on Wednesday June 11, 2025 at 10:00 A.M., to deliberate on the attached agenda. The OGM will be held in ...
IBA (Ion Beam Applications), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results